Free Trial

Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down - Here's What Happened

Hikma Pharmaceuticals logo with Medical background

Key Points

  • Hikma Pharmaceuticals' shares gapped down from a previous close of $27.96 to an opening price of $26.38, reflecting a notable decline in value.
  • Analysts at BNP Paribas have issued an "outperform" rating for Hikma Pharmaceuticals, signaling potential for positive performance despite the recent stock decline.
  • The company's 50-day and 200-day simple moving averages are $27.73 and $26.99, respectively, indicating a general trend of weakening stock performance.
  • Looking to export and analyze Hikma Pharmaceuticals data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $27.96, but opened at $26.38. Hikma Pharmaceuticals shares last traded at $26.38, with a volume of 200 shares changing hands.

Analyst Ratings Changes

Separately, BNP Paribas started coverage on Hikma Pharmaceuticals in a research note on Tuesday, May 13th. They issued an "outperform" rating on the stock.

Get Our Latest Report on Hikma Pharmaceuticals

Hikma Pharmaceuticals Stock Performance

The stock's 50 day moving average is $27.65 and its 200 day moving average is $27.03. The company has a quick ratio of 0.65, a current ratio of 1.14 and a debt-to-equity ratio of 0.28.

About Hikma Pharmaceuticals

(Get Free Report)

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.

Featured Stories

Should You Invest $1,000 in Hikma Pharmaceuticals Right Now?

Before you consider Hikma Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hikma Pharmaceuticals wasn't on the list.

While Hikma Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Next Tech Boom: AI Robots Are Coming Sooner Than You Think!
Tech Stocks Stumble: Will Nvidia’s Report Spark a Rebound?
Follow the Money: 5 Stocks Institutions Are Buying NOW

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines